NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

TikToker Insightful Lucy has revealed the four things she wished she had known before starting Mounjaro, after losing six stone on the medication.

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

By Mariam Sunny (Reuters) -U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

In this episode of The NBR Podcast with Simon Shepherd: Obesity. Conservatively, it's a two-billion-dollar problem. But the ...